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Abstract. – OBJECTIVE: Recently, two in-
fluential articles that reported the association 
of (hydroxy)chloroquine or angiotensin con-
verting enzyme (ACE) inhibitors and coronavi-
rus disease 2019 (COVID-19) mortality were re-
tracted due to significant methodological is-
sues. Therefore, we aimed to analyze the same 
clinical issues through an improved research 
method and to find out the differences from the 
retracted papers. We systematically reviewed 
pre-existing literature, and compared the re-
sults with those of the retracted papers to gain 
a novel insight.
MATERIALS AND METHODS: We extracted 
common risk factors identified in two retract-
ed papers, and conducted relevant publication 
search until June 26, 2020 in PubMed. Then, we 
analyzed the risk factors for COVID-19 mortal-
ity and compared them to those of the retract-
ed papers. 
RESULTS: Our systematic review demonstrat-
ed that most demographic and clinical risk fac-
tors for COVID-19 mortality were similar to those 
of the retracted papers. However, while the re-
tracted paper indicated that both (hydroxy)chlo-
roquine monotherapy and combination therapy 
with macrolide were associated with higher risk 
of mortality, our study showed that only combi-
nation therapy of hydroxychloroquine and mac-
rolide was associated with higher risk of mor-
tality (odds ratio 2.33; 95% confidence interval 
1.63-3.34). In addition, our study demonstrat-
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ed that use of ACE inhibitors or angiotensin re-
ceptor blockers (ARBs) was associated with re-
duced risk of mortality (0.77; 0.65-0.91).
CONCLUSIONS: When analyzing the same 
clinical issues with the two retracted papers 
through a systematic review of randomized con-
trolled trials and relevant cohort studies, we 
found out that (hydroxy)chloroquine monother-
apy was not associated with higher risk of mor-
tality, and that the use of ACE inhibitors or ARBs 
was associated with reduced risk of mortality in 
COVID-19 patients.
Key Words:
COVID-19, Risk factors, Mortality.
Introduction
Since the coronavirus disease 2019 
(COVID-19) outbreak first emerged in Decem-
ber 2019, many studies have confirmed the 
risk factors related to mortality in COVID-191. 
Among them, two studies conducted by the team 
of Mehra et al2,3 raised critical issues about the 
treatment of chloroquine or hydroxychloroquine 
and the use of angiotensin-converting enzyme 
(ACE) inhibitors or angiotensin receptor block-
ers (ARBs) in COVID-19 patients. The study of 
chloroquine or hydroxychloroquine treatment 
included 96,032 COVID-19 patients, and the 
results showed that chloroquine or hydroxychlo-
roquine treatment, when used alone or in com-
bination with a macrolide, had no clinical ben-
efits, but rather, a risk of increasing in-hospital 
mortality. The study was published in Lancet2, 
and had a significant impact on clinical prac-
tice, halting other relevant clinical trials. The 
other study on the use of ACE inhibitors and 
ARBs enrolled 8,910 COVID-19 patients and 
demonstrated that there was no increased risk of 
in-hospital mortality associated with their use. 
The study was published in the New England 
Journal of Medicine (NEJM)3. Unfortunately, 
these two articles were retracted due to critical 
ethical issues, not all authors were not granted 
access to the raw data, and the data could not be 
made available to a third-party auditor.
Thus, more reliable studies are needed through 
improved research methods. In this study, we 
tried to analyze the same clinical issues through 
a systematic review of randomized controlled 
trials (RCTs) and relevant cohort studies. Then, 
we aimed to find novel findings by comparing the 
studies of Mehra et al2,3.
Materials and Methods
Search Strategy
We identified risk factors associated with 
COVID-19 mortality, which were also previously 
evaluated in the studies of Mehra et al2,3. Then, 
we performed literature search until June 26, 
2020 in PubMed by using several key terms. The 
search terms used were divided into three groups: 
the risk factors (i.e., “Age” “Age older than 65 
years” “Body mass index (BMI) greater than 35” 
“Male” “Ethnicity” “Black” “Hispanic” “Asian” 
“Cardiovascular diseases” “Cerebrovascular 
disease” “Cardiac injury” “Myocardial injury” 
“Congestive heart failure” “Diabetes mellitus” 
“Arterial hypertension” “Hypertension” “Hyper-
lipidemia” “Chronic obstructive pulmonary dis-
ease (COPD)” “Respiratory disease” “Smoking” 
“Autoimmune disease” “Cancer” “Cancer che-
motherapy” “Cancer immunotherapy” “Cortico-
steroid use” “ACE inhibitor use” “Angiotensin 
receptor blocker use” “ACE inhibitor/ARB” “Ox-
ygen saturation (SpO2) below 60%”, “Sequential 
organ failure assessment (SOFA)” “Chloroquine 
use” “Hydroxychloroquine use” or “Hydroxy-
chloroquine or macrolide” “Hydroxychloro-
quine and macrolide use in combination”) AND 
“mortality” AND COVID-19 related terms (i.e., 
“COVID-19” or “SARS-CoV-2”). The inclusion 
criterion for evaluating the eligibility of identified 
articles in the respect of study design included 
cohort studies, case-control studies, case series, 
and RCTs. The selection of articles based on 
study designs was performed with an emphasis 
on RCTs. Furthermore, the selection process of 
articles for evaluating the effects of risk factors 
on COVID-19 mortality was carried out by pri-
oritizing articles in a recent order and screening 
studies with a large number of participants. Fi-
nally, we selected studies reporting hazard ratio 
(HR), odds ratio (OR), and relative risk (RR) with 
a significant confidence interval (95% CI) and 
p-value (p<0.05), and then, we used studies with 
low I2 value (Supplementary Table I).
Results 
Summary of Systematic review on 
Risk Factors for Mortality in 
COVID-19 Patients 
As for demographic and clinical risk factors, 
age greater than 65 years, BMI greater than 35, 
male sex, black race and Asian ethnicity, coronary 
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artery disease, congestive heart failure, diabetes 
mellitus, hypertension, COPD, current smoker, 
immunosuppressed condition by corticosteroids 
and high severity of illness (high score of SOFA 
or SpO2 <94%) were associated with higher risk 
of mortality in COVID-19 (Table I). As for med-
ications, hydroxychloroquine with macrolide was 
associated with higher risk of COVID-19 mortal-
ity (OR 2.33; 95% CI 1.63-3.34). In contrast, the 
use of ACE inhibitors or ARBs was associated 
with reduced risk of mortality (OR 0.77; 95% CI 
0.65-0.91) (Table II). No association was found 
for hyperlipidemia, cancer chemotherapy, and 
chloroquine or hydroxychloroquine monotherapy.
Comparison with the Studies of Mehra 
et al2,3 in Lancet and NEJM
The studies of Mehra et al2,3 in Lancet and the 
NEJM showed similar results in the demographic 
and clinical risk factors for COVID-19 mortality 
because they commonly used the data from the 
same multinational registry. In their study, vari-
ables associated with higher in-hospital mortality 
included advanced age, high BMI, black race 
or Hispanic ethnicity, coronary artery disease, 
congestive heart failure, arrhythmia, diabetes, 
hypertension, hyperlipidemia, COPD, current 
smoker, and SpO2 <94%. Favorable variables 
included female sex, Asian ethnicity and qSOFA 
<1 (Table I). The Lancet study2 comprised of 
five groups; control, chloroquine alone, hydroxy-
chloroquine alone, chloroquine with macrolide, 
and hydroxychloroquine with a macrolide. Com-
pared with the control group, chloroquine alone 
(HR 1.365; 95% CI 1.218-1.531), hydroxychlo-
roquine alone (1.335; 1.223-1.457), chloroquine 
with macrolide (1.368; 1.273-1.469), and hydroxy-
chloroquine with macrolide (1.447; 1.368-1.531) 
were independently associated with increased 
risk of in-hospital mortality (Table II). Mehra et 
al2 concluded that COVID-19 treatment based 
on chloroquine or hydroxychloroquine with or 
without macrolide had no clinical benefits and 
was associated with increased risk of in-hospital 
mortality. The study also showed the risk factors 
of clinically significant ventricular arrhythmias2. 
Variables including coronary artery disease, con-
gestive heart failure, arrhythmia, and COPD were 
independently associated with increased risk of 
de-novo ventricular arrhythmias during hospital-
ization. Compared with the control group, chlo-
roquine alone (HR 3.561; 95% CI 2.760-4.596), 
hydroxychloroquine alone (2.369; 1.935-2.900), 
chloroquine with macrolide (4.011; 3.344-4.812), 
and hydroxychloroquine with macrolide (5.106; 
4.106-5.983) were independently associated with 
an increased risk of de-novo ventricular arrhyth-
mia during hospitalization2. These findings are 
consistent with previous studies that have shown 
the association between the given treatment reg-
imens and QT interval prolongation that leads to 
ventricular arrhythmias4. As for the ACE inhib-
itors and ARBs, Lancet2 and the NEJM3 studies 
showed reduced risk of in-hospital mortality in 
the use of ACE inhibitors (Lancet: HR 0.566; 
95% CI 0.514-0.624, NEJM: OR 0.33; 95% CI 
0.20-0.54), whereas no association was found 
between ARBs and mortality. The studies also 
showed that the use of statin was associated with 
reduced risk of in-hospital mortality (Lancet: HR 
0.793; 95% CI 0.736-0.855, NEJM: OR 0.35; 95% 
CI 0.24-0.52) (Table II).
In comparison with the studies of Mehra et 
al2,3, our systematic review showed similar trends 
for most demographic (Figure 1) and clinical 
variables (Figure 2). However, unlike the study 
of Mehra et al2, Asian ethnicity has been iden-
tified as an unfavorable risk factor in our study 
(HR 1.62; 95% CI 1.43-1.82). Furthermore, while 
the study of Mehra et al2 indicated that mono-
therapy with chloroquine or hydroxychloroquine 
was associated with increased risk of in-hospital 
mortality, our study showed that chloroquine or 
hydroxychloroquine monotherapy was not asso-
ciated with higher risk of mortality. Our system-
atic review demonstrated that only combination 
therapy of hydroxychloroquine and macrolide 
was associated with higher risk of mortality 
(Figure 3). As for the use of ACE inhibitors or 
ARBs, although we could not perform analysis 
for each drug separately, the results showed a 
better chance of survival with the use of ACE 
inhibitors or ARBs (Figure 3).
Discussion 
Recent publications in the Lancet and the NE-
JM by the team of Mehra et al2,3 were primarily 
based on a database run by an American health-
care analytics company named Surgisphere. Ma-
ny clinicians and researchers around the world 
criticized Surgisphere for multiple reasons, in-
cluding the company’s refusal to disclose the raw 
data and making claims that did not match pub-
licly available government reports. For example, 
Sugisphere’s data on the number of Polymerase 
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Australia, the United Kingdom, and Turkey were 
higher than numbers reported by each country’s 
government. Critics have urged Surgisphere to 
disclose aggregated patient data at a hospital 
level, but the company failed to validate the in-
tegrity of its data5,6. As a result, Lancet and the 
NEJM papers by the Mehra’s research team2,3 
were retracted, and moreover, many researchers 
have still criticized that some clinical trials have 
been discontinued by the study of Mehra et al2, 
although the study was not a RCT, and the results 
were significantly limited.
On the other hand, our study aimed to ver-
ify clinical risk factors related to COVID-19 
mortality through a systematic literature review 
unlike the retracted papers in which analyzing 
data were collected by a single data company. 
Our study have selected relevant studies with an 
Figure 2. Comparison of the effect of underlying clinical conditions on COVID-19 mortality between systematic review and 
Mehra et al2,3 studies.
Figure 1. Comparison of the effect of demographic characteristics on COVID-19 mortality between systematic review and 
Mehra et al2,3 studies. *In the retracted Lancet2 and NEJM3 papers, Mehra et al2,3 reported effect size based on female sex. 
**Publications that were reviewed in this study reported effect size based on male sex.
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emphasis on RCTs even among various study de-
signs and the cohort studies with a large number 
of participants to control the quality of data to 
be examined. As a result, our study confirmed 
that advanced age, high BMI, male sex, black 
race, current smoker, and comorbidities, such 
as hypertension, diabetes mellitus, coronary ar-
tery disease, congestive heart failure, and COPD 
were still significant risk factors for increased 
mortality in COVID-19 patients. In addition, our 
study reported a conflicting result with the study 
of Mehra et al2 regarding ethnicity. In our study, 
Asian ethnicity appeared as a significant risk fac-
tor for COVID-19 mortality. A recent study7 also 
demonstrated that “South Asian ethnicity” had 
1.45 times increased risk of COVID-19 mortality 
supporting our study result.
More noteworthy is the difference in the results 
on the relationship of chloroquine or hydroxy-
chloroquine and COVID-19 mortality. Mehra et 
al2 showed that chloroquine or hydroxychloro-
quine monotherapy, as well as combination ther-
apy with macrolide, was associated with higher 
in-hospital mortality. In addition, they showed 
that chloroquine or hydroxychloroquine was as-
sociated with the occurrence of ventricular ar-
rhythmias during hospitalization, whether treated 
alone or in combination with macrolide. Howev-
er, our study demonstrated that only combination 
therapy of hydroxychloroquine and macrolide 
was associated with higher risk of COVID-19 
mortality.
Many researchers and clinicians have been 
concerned about the clinical risk of dangerous 
ventricular arrhythmias leading to mortality af-
ter the use of chloroquine or hydroxychloroquine 
in the treatment of COVID-19. The underlying 
mechanism has been known to be related to the 
pharmacologic effects whereby cardiac QT inter-
val is prolonged4. In particular, macrolide is also 
known to contribute to QT prolongation8. There-
fore, the combination treatment of chloroquine or 
hydroxychloroquine and macrolide is expected to 
increase significantly the pharmacologic effects 
that cause QT prolongation. In this regard, our 
study indicates that chloroquine or hydroxychlo-
roquine monotherapy would not have a sufficient 
effect on the occurrence of clinically significant 
ventricular arrhythmia leading to mortality. A 
recent meta-analysis also showed that only com-
bined use of hydroxychloroquine and azithromycin 
was associated with an increase in mortality, while 
hydroxychloroquine alone was not9. Then, why did 
the study of Mehra et al2 show that chloroquine or 
hydroxychloroquine monotherapy was associated 
with mortality? Many researchers have pointed out 
the dosage of chloroquine or hydroxychloroquine 
used in the study of Mehra et al2 was higher than 
Figure 3. Comparison of the effect of medications on COVID-19 mortality between systematic review and Mehra et al2,3 
studies.
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the recommended dosage. In the study of Mehra et 
al2, the mean daily dose administered in monother-
apy was 765 mg for chloroquine and 596 mg for 
hydroxychloroquine. Although the United States 
Food and Drug Administration (FDA) has current-
ly canceled the Emergency Use of Authorization 
(EUA) for chloroquine and hydroxychloroquine 
to treat COVID-19, the dosage used in the study 
exceeded what has been previously recommended 
by FDA. The suggested maintenance dose in the 
EUA for chloroquine was 500 mg daily, and hy-
droxychloroquine was 400 mg daily10,11. Although 
the optimal dosing of treatment of COVID-19 is 
not established, given that many other studies have 
followed the FDA’s recommendations, it is con-
ceivable that higher dosage may have affected the 
results in the study of Mehra et al2. Taken together, 
we believe that if not used with macrolide or used 
with appropriate dosage, chloroquine or hydroxy-
chloroquine monotherapy as a treatment option 
for COVID-19 might have a low clinical risk for 
ventricular arrhythmias leading to mortality.
Nevertheless, the use of chloroquine or hy-
droxychloroquine in the treatment of COVID-19, 
whether alone or in combination, is still not rec-
ommended by recent findings. The recent review 
indicated that the evidence regarding the clini-
cal benefit of hydroxychloroquine on COVID-19 
was found to be weak and insufficient12-14. Fur-
thermore, on July 4, 2020, WHO discontinued 
hydroxychloroquine arm of the Solidarity trial 
because the interim result revealed that hydroxy-
chloroquine produced no benefit over the mor-
tality of hospitalized COVID-19 patients when 
compared to the standard of care15. 
The other important issue is the use of ACE 
inhibitors or ARBs in COVID-19 pandemic. Ma-
ny researchers and clinicians have been con-
cerned that the use of these drugs would wors-
en COVID-19 risk. However, our systematic re-
view showed that the use of ACE inhibitors or 
ARBs was rather associated with lower risk of 
COVID-19 mortality. Due to the lack of pre-ex-
isting researches that examined ACE inhibitors 
or ARBs as distinct clinical factors, we could not 
identify the individual effect of ACE inhibitors or 
ARBs on COVID-19 mortality. ACE inhibitors 
and ARBs have been speculated to have a dual 
role in COVID-19 pathogenesis, as both medica-
tions may increase the expression of Angioten-
sin-converting enzyme 2 (ACE2). An increase 
in the number of ACE2 may enhance the risk of 
infection because ACE2 is a cellular receptor that 
Severe Acute Respiratory Syndrome Coronavirus 
2 (SARS-CoV-2) binds to when entering the host 
cell16. On the contrary, ACE2 can exert anti-in-
flammatory effects, reducing the severity of lung 
damage caused by COVID-1917. Although further 
investigation is needed to fully understand each 
medication’s role in COVID-19 pathogenesis and 
to identify the dominant effect of increased ACE2 
expression, our study suggests the clinical safety 
and possible benefit of ACE inhibitors or ARBs 
in COVID-19.
Relating to study design, one limitation that 
we were not able to rule out was the possibility 
of selection bias. There are several tools that help 
to exclude selection bias and design a well-de-
veloped study. For example, PRISMA helps to 
set the inclusion criteria to avoid selection bias18. 
Since our study did not establish inclusion criteria 
according to such protocols, there is a possibility 
of selection bias. Furthermore, quality assessment 
has not been done in the present study, and this 
also introduces the risk of selection bias. Another 
problem is that several studies used in our work 
were conducted with different research methods. 
This heterogeneity of the methods results in a 
broad range of CIs. Moreover, in Lancet, HR 
is used to assess the mortality risk, whereas, in 
the NEJM, it is assessed by OR. These reduce 
the credibility of the results given by our data, 
which also may have led to erroneous inferences 
on results.
Conclusions
In this study, we have verified risk factors for 
COVID-19 mortality through systematic review 
of RCTs and cohort studies in comparison with 
the studies of Mehra et al2,3. Our data indicate that 
chloroquine or hydroxychloroquine monotherapy 
is not associated with increased risk of mortality, 
and ACE inhibitors or ARBs was associated with 
reduced risk of mortality in COVID-19 patients.
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